Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?

There is currently deep uncertainty about the clinical benefits and cost effectiveness of highly specialised technologies (HSTs), like gene and cell therapies. These treatments are novel, typically have high upfront costs, the patient populations are small and heterogenous, there is minimal informat...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlin, Tracy, Street, Jackie, Carter, Drew, Haji Ali Afzali, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628011/
https://www.ncbi.nlm.nih.gov/pubmed/37824056
http://dx.doi.org/10.1007/s40258-023-00835-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628011/
https://www.ncbi.nlm.nih.gov/pubmed/37824056
http://dx.doi.org/10.1007/s40258-023-00835-3

Ejemplares similares